
BENZTROPINE MESYLATE- benztropine tablet Cipla USA Inc.

Benztropine Mesylate Tablets, USP

DESCRIPTION

Benztropine mesylate, USP is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is a crystalline white powder, very soluble in water, designated as 3α -(Diphenylmethoxy)- 1α H, 5α H-tropane methanesulfonate, with the following structural formula:



 $C_{21}H_{25}NO \cdot CH_4O_3S$

MW 403.55

Each tablet, for oral administration, contains 0.5 mg, 1 mg or 2 mg of benztropine mesylate USP.

Each tablet contains the following inactive ingredients: lactose anhydrous, micro-crystalline cellulose, colloidal silicon dioxide, sodium starch glycolate and magnesium stearate.

CLINICAL PHARMACOLOGY

Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.

In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.

In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.

INDICATIONS AND USAGE

For use as an adjunct in the therapy of all forms of parkinsonism.

Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see **PRECAUTIONS**) due to neuroleptic drugs (e.g., phenothiazines).

CONTRAINDICATIONS

Hypersensitivity to benztropine mesylate tablets.

Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

WARNINGS

Safe use in pregnancy has not been established.

Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.

Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

PRECAUTIONS

General

Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.

Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine mesylate.

The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.

Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.

Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate is not recommended for use in patients with tardive dyskinesia.

The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in

angle-closure glaucoma.

Drug Interactions

Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see **WARNINGS**).

Pediatric Use

_

Because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see **CONTRAINDICATIONS**).

ADVERSE REACTIONS

The adverse reactions below, most of which are antichlolinergic in nature, have been reported and within each category are listed in order of decreasing severity.

Cardiovas cular

Tachycardia.

Digestive

Paralytic ileus, constipation, vomiting, nausea, dry mouth.

If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.

Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.

Nervous System

Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.

Special Senses

Blurred vision, dilated pupils.

Urogenital

Urinary retention, dysuria.

Metabolic/Immune or Skin

Occasionally, an allergic reaction, e.g., skin rash, develops. If this can not be controlled by dosage reduction, the medication should be discontinued.

Other

Heat stroke, hyperthermia, fever.

OVERDOSAGE

Manifestations – May be any of those seen in atropine poisoning or antihistamine overdosage: CNS depression, preceded or followed by stimulation; confusion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); hallucinations (especially visual); dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; tachycardia; elevated blood pressure; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e.g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.

Treatment – Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication. * A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose convulsive, or psychotic states). Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.

DOSAGE AND ADMINISTRATION

Benztropine mesylate tablets should be used when patients are able to take oral medication.

Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.

Postencephalitic and Idiopathic Parkinsonism – The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg orally.

As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.

In idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime. In some patients, this will be adequate; in others 4 to 6 mg a day may be required.

In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.

Some patients experience greatest relief by taking the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.

The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.

When benztropine mesylate is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.

Benztropine mesylate may be used concomitantly with Carbidopa- Levodopa, or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response.

Drug-Induced Extrapyramidal Disorders – In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day orally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.

When extrapyramidal disorders develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate tablets two or three times a day usually provides relief within one or two days. After one or two weeks the drug should be withdrawn to determine the continued need for it. If such disorders recur, benztropine mesylate can be reinstituted.

Certain drug-induced extrapyramidal disorders that develop slowly may not respond to benztropine mesylate.

HOW SUPPLIED

Benztropine Mesylate Tablets, USP are available as follows:

0.5 mg white, capsule shaped biconvex tablets de-bossed with 'I' on the left side of bisect and 'G'on the right side of the bisect and "318" on the other side, supplied in bottles of 30 (NDC 69097-826-02), 100 (NDC 69097-826-07) and 1000 (NDC 69097-826-15).

1 mg white, modified oval biconvex tablets de-bossed with "I" on the left side of bisect and "G" on the right side of the bisect on one side and "319" on the other side, supplied in bottles of 30 (NDC 69097-827-02), 100 (NDC 69097-827-07) and 1000 (NDC 69097-827-15).

2 mg white, round, flat faced beveled edged tablets de-bossed with 'I' on the left side of bisect and 'G' on the right side of the bisect and "320" on the other side, supplied in bottles of 30 (NDC 69097-832-02), 100 (NDC 69097-832-07) and 1000 (NDC 69097-832-15).

Dispense in a well-closed container as defined in the USP.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

*Duvoisin, R.C.; Katz, R.J.; Amer. Med.Ass. 206:1963-1965, Nov. 25, 1968.

Manufactured by:

InvaGen Pharmaceuticals, Inc.

(a subsidiary of Cipla Ltd.)

Hauppauge, NY 11788

Manufactured for:

Cipla USA, Inc.

10 Independence Boulevard, Suite 300 Warren, NJ 07059

Revised: 02/2020

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 69097-826-07 Rx Only Benztropine Mesylate Tablets, USP 0.5 mg 100 Tablets Cipla



NDC 69097-827-07

Benztropine

Mesylate

Tablets, USP

1 mg

100 Tablets

Cipla



NDC 69097-832-07 Benztropine Mesylate **Rx Only**

Rx Only

Tablets, USP 2 mg 100 Tablets Cipla



BENZTROPINE M	ESYL	ATE					
oenztropine tablet							
Product Information							
Product Type		HUMAN PRESCRIPTIO	ON DRUG	Item Cod	e (Source)	NDC:690	97-826
Route of Administration	ation ORAL						
Active Ingredient/Acti							
	Ingi	redient Name			Basis of St	trength	Strength
BENZTROPINE MESYLATE (UNII: WMJ8TL7510) (BENZTROPINE - UNII:1NHL2J4X8K) BENZTROPINE MESYL					MESYLATE	0.5 mg	
Inactive Ingredients							
		Ingredient N	lame			S	trength
ANHYDROUS LACTOSE (UI	NII: 3SY5LI	H9 PMK)					
MICRO CRYSTALLINE CEL	LULOSE (UNII: OP1R32D61U)					
SILICON DIO XIDE (UNII: ET	J7Z6XBU4	4)					
SODIUM STARCH GLYCOL	АТЕ ТҮРІ	E A POTATO (UNII: 5	856J3G2A2)				
MAGNESIUM STEARATE (U	NII: 70097	M6I30)					
Product Characteristic	cs						
i i oudet Characteristi			a.			2 pieces	
Color	WHITE		Score			2 pieces	
	WHITE CAPSUL	.E	Score Size			4mm	

Contains								
Packaging								
# Item Code		on	Marketi	ng Start Date	te Marketing End Dat			
NDC:69097-826-02	30 in 1 BOTTL	E; Type 0: Not a Comb	nation Product	06/29/201	.6			
2 NDC:69097-826-07				06/29/2016				
B NDC:69097-826-15	1000 in 1 BOT	ГLЕ; Туре 0: Not a Cor	nbination Product	06/29/201	.6			
Marketing Info	rmation							
Marketing Category				ion Marketing Start Date Marketing				
ANDA	ANDA09029	4		06/29/2016				
BENZTROPINI	E MESYL	ATE						
penztropine tablet								
Product Informati	on							
Product Type		HUMAN PRESCRIPTIO	ON DRUG	Item Code (Source) NI		NDC:690	DC:69097-827	
Route of Administrati	on	ORAL						
Active Ingredient/	Active Moi	etv						
i cure ingreuiend		redient Name			Basis of S	trength	Strengtl	
BENZTRO PINE MES YL	0)PINE - UNII:1NHL.	2J4X8K)	BENZTROPINE	-	1 mg	
Inactive Ingredien	its							
		Ingredient N	lame			S	trength	
ANHYDROUS LACTOS								
MICROCRYSTALLINE		, ,						
SILICON DIOXIDE (UN		,						
SODIUM STARCH GLY			856J3G2A2)					
MAGNESIUM STEARAT	TE (UNII: 7009	/ M6 130)						
Product Character	ristics							
Color	WHITE		S	core		2 pieces		
Shape	OVAL ((modifi	S	ize		4mm	4mm		
Flavor			Ь	Imprint Code				
Contains								
Dackaging								
Packaging								
# Item Code		Package Descripti	0 n	Marketi	ng Start Date	Marketing	g End Date	

		JU III I DU I I LI	E; Type 0: Not a Combination Product	06/29/	2016			
- NDC.09097-0	827-07	100 in 1 BOTTI	E; Type 0: Not a Combination Produc	t 06/29/	2016			
3 NDC:69097-8	827-15	1000 in 1 BOTT	LE; Type 0: Not a Combination Produ	ict 06/29/	2016			
Marketing	g Info	ormation						
Marketing Ca	tegory	Applicatio	n Number or Monograph Citatio	n Mark	eting Start Date	e Marketin	g End Date	
ANDA		ANDA090294	1	06/29/2	2016			
BENZTRC Denztropine ta		E MESYL	АТЕ					
Product Inf		ion						
Product Type		1011	HUMAN PRESCRIPTION DRUG	Ite m C	Code (Source)	NDC:69	097-832	
Route of Admi		tion	ORAL		(202200)			
Active Ingre	edient	Active Moi	•				Q .	
		_	redient Name Ø8TL7510) (BENZTROPINE - UNII:1N			f Strength NE MESYLATE	Strengt	
Inactive Ing	redie	nts						
			Ingredient Name			:	Strength	
ANHYDRO US I	LACTO	SE (UNII: 3SY5L	Н9 РМК)			5	Strength	
ANHYDROUS I MICROCRYST	LACTO	SE (UNII: 3SY5L E CELLULOSE	H9 PMK) (UNII: O P1R32D6 1U)				Strength	
SILICON DIO X	LACTO ALLINE (UI	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6XBU	H9 PMK) (UNII: OP1R32D6 1U) 4)				Strength	
ANHYDRO US I MICRO CRYST. SILICO N DIO X SO DIUM STAR	LACTO ALLINE KIDE (UN	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6XBU YCOLATE TYP	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2)				Strength	
ANHYDRO US I MICRO CRYST. SILICON DIO X SO DIUM STAR	LACTO ALLINE KIDE (UN	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6XBU YCOLATE TYP	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2)				Strength	
ANHYDRO US I MICRO CRYST SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Ch a	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6XBU YCOLATE TYP TE (UNII: 70097 ristics	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)					
ANHYDRO US I MICRO CRYST. SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Ch a Color	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70093 ristics WHITE	H9PMK) (UNII: OP1R32D61U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6130)	Score		2 piece		
ANHYDRO US I MICRO CRYST SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shape	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6XBU YCOLATE TYP TE (UNII: 70097 ristics	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)	Size		2 piece 6mm	25	
ANHYDRO US I MICRO CRYST. SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shape Flavor	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70093 ristics WHITE	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)		.de	2 piece	25	
ANHYDRO US I MICRO CRYST. SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shape Flavor	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70093 ristics WHITE	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)	Size	de	2 piece 6mm	25	
ANHYDRO US I MICRO CRYST. SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shap e Flavor Contains	LACTO ALLINE (IDE (UI CH GL [*] TEARA	SE (UNII: 3SY5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70093 ristics WHITE	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)	Size	nd e	2 piece 6mm	25	
ANHYDROUS I MICROCRYST. SILICON DIOX	ACTO ALLINE IDE (UI CH GL TEARA	SE (UNII: 3S Y5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70097 ristics WHITE ROUND ((flat	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6 I30)	Size Imprint Co	de eting Start Dat	2 pie ce 6 mm 1G;320	e s	
ANHYDRO US I MICRO CRYST SILICON DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shape Flavor Contains Packaging # Item Co	ACTO ALLINE CIDE (UI CCH GL [*] TEARA aracte	SE (UNII: 3S Y5L E CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 7009) TE (UNII: 7009) RUSS WHITE ROUND ((flat	H9 PMK) (UNII: OP1R32D6 1U) 4) E A POTATO (UNII: 5856 J3G2A2) 7M6 I30) faced)) faced))	Size Imprint Co Mark	eting Start Dat	2 pie ce 6 mm 1G;320	e s	
ANHYDRO US I MICRO CRYST SILICO N DIO X SO DIUM STAR MAGNESIUM S Product Cha Color Shape Flavor Contains Packaging # Item Co 1 NDC:69097-8	ACTO ALLINE CDE (UI CCH GL) TEARA aracte	SE (UNII: 3SY5L CELLULOSE NII: ETJ7Z6 XBU YCOLATE TYP TE (UNII: 70097 TE (UNII: 70097 NHITE ROUND ((flat 30 in 1 BOTTLH	H9PMK) (UNII: OP1R32D61U) 4) E A POTATO (UNII: 5856J3G2A2) 7M6I30) faced)) faced)) Package Description	Size Imprint Co Mark 06/29/	eting Start Dat 2016	2 pie ce 6 mm 1G;320	e s	

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANDA	ANDA090294	06/29/2016			

Labeler - Cipla USA Inc. (078719707)

Registrant - Cipla USA Inc. (078719707)

Establishment

Name	Address		Business Operations
InvaGen Pharmaceutical Inc		165104469	analysis(69097-826, 69097-827, 69097-832) , manufacture(69097-826, 69097-827, 69097-832)

Establishment

Name	Address	ID/FEI	Business Operations
InvaGen Pharmaceutical Inc		080334903	analysis(69097-826, 69097-827, 69097-832), pack(69097-826, 69097-827, 69097-832)

Revised: 5/2020

Cipla USA Inc.